Back

Effect of sodium-glucose cotransporter 2 inhibitors (SGLT2) on the occurrence of tachyarrhythmias in patients with heart failure with reduced ejection fraction

13 April 2026 (08:30 - 09:15)
Organised by: Logo
Congress Presentation Part of: Antiarrhythmic drugs Antiarrhythmic Drug Treatment EHRA Premium Access EHRA 2026 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Juan Jose Serrano Silva

General Hospital of Jerez, Jerez de la Frontera (Spain)

5 More presentations in this session

Presentation thumbnail
Results of a national survey on ethacizine for atrial fibrillation treatment in real practice as a part of a patient oriented approach
Professor N. Sydorova (Kiev, UA)
Abstract Slides Video
Presentation thumbnail
The influence of digoxin on outcomes in remotely monitored patients with implantable cardioverter-defibrillators
Doctor M. Dyrbus (Zabrze, PL)
Abstract Slides Video
Presentation thumbnail
Flecainide in the treatment of high premature ventricular contractions burden: preliminary results from the UNIFLECA study
Doctor S. Kotoulas (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Can colchicine tame atrial fibrillation? A scoping review
Miss S. Hasan (Coventry, GB)
Abstract Slides Video
Presentation thumbnail
Comparative outcomes of amiodarone and dronedarone in atrial fibrillation: a real-world retrospective cohort study
Doctor A. Akuka (Holon, IL)
Abstract Slides Video

Access the full session

Session thumbnail
Antiarrhythmic drugs

The Event

Event poster

EHRA 2026

13 April 2026 08:30 CET
You may be interested in
thumbnail
Congress Presentation
Impact of SLGT2 inhibitors treatment initiation on the reduction of atrial and ventricular arrhythmias in patients with implanted cardiac device
thumbnail
Congress Presentation
Impact of SLGT2 inhibitors treatment initiation on the reduction of atrial and ventricular arrhythmias in patients with implanted cardiac defibrillator
thumbnail
Congress Presentation
Effect of SGLT2 inhibitors in sustained ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators for primary prevention

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources